Related Experiment Video
Updated: Jun 30, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
T-cell regulation in asthmatic diseases
1Laboratory of Cellular and Molecular Lung Immunology, First Medical Clinic, Mainz, Germany.
Chemical Immunology and Allergy
|September 20, 2008
Summary
T cells, including effector and regulatory T cells (Tregs), are key to allergic asthma. Understanding their roles in inflammation and immune balance may lead to new asthma treatments.
Area of Science:
- Immunology
- Respiratory Medicine
Background:
- T cells, specifically effector and regulatory T cells (Tregs), are crucial in the airways for allergic asthma.
- The immunopathogenesis of asthma involves complex T cell interactions.
Purpose of the Study:
- To review the role of T cells in the immunopathogenesis of human asthma and animal models.
- To highlight the functions of effector T cells (Th2, Th17) and Tregs in airway inflammation.
Main Methods:
- Review of existing literature on T cell subsets (Th2, Th17, Tregs) and their associated transcription factors (T-bet, GATA-3, ROR-gammat, Foxp3).
- Discussion of cytokine signaling pathways influencing T cell development and activation.
- Examination of experimental data, including cytokine blockade studies (e.g., IL-6R).
Main Results:
- Th2 and Th17 effector T cells exacerbate experimental airway inflammation.
- Regulatory T cells (Tregs) exert anti-inflammatory effects.
- Transcription factors like GATA-3, T-bet, ROR-gammat, and Foxp3 are critical for T cell subset differentiation.
- Cytokine signaling regulates T cell subsets; IL-6R blockade can induce Tregs.
Conclusions:
- Allergic asthma is a complex disease significantly influenced by T lymphocyte activity.
- Human asthmatics may exhibit increased Th2 cells and decreased Tregs, with Th17 roles still under investigation.
- Further understanding of effector and Treg cell activation is essential for developing novel asthma therapies.
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...